- Home
- MDGL
as 08-22-2025 4:00pm EST
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WEST CONSHOHOCKEN |
| Market Cap: | 6.1B | IPO Year: | N/A |
| Target Price: | $445.71 | AVG Volume (30 days): | 469.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -12.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $200.63 - $419.99 | Next Earning Date: | 08-05-2025 |
| Revenue: | $515,547,000 | Revenue Growth: | 3421.98% |
| Revenue Growth (this year): | 286.67% | Revenue Growth (next year): | 67.98% |
Latest Madrigal Pharmaceuticals Inc. News
MDGL Breaking Stock News: Dive into MDGL Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Pharmaceutical Technology
2 months ago
Madrigal poised to enter European MASH market after CHMP endorsement
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise Premarket Friday
MT Newswires
2 months ago
Exchange-Traded Funds Slightly Higher, Equity Futures Mixed Pre-Bell Friday as Geopolitical, Trade Risks Mount
MT Newswires
2 months ago
Madrigal Gets Positive Opinion From EMA for Resmetirom to Treat Liver Disease
GlobeNewswire
2 months ago
Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis
GlobeNewswire
2 months ago
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Simply Wall St.
2 months ago
Exploring High Growth Tech Stocks In The US Market
Compare MDGL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MDGL Madrigal Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.